Melanotan II is an unapproved synthetic analog of alpha-melanocyte-stimulating hormone, and no regulatory body has authorized it for human use, so no validated or standardized dosing regimen exists. Every figure in circulation traces to informal user practice and gray-market vendor material rather than approved labeling or controlled clinical guidance. In practice the compound is sold as a lyophilized powder that the end user reconstitutes and injects subcutaneously, entirely outside pharmacist or prescriber oversight.
Melanotan II is not FDA-approved and has no validated dosing standard, so every dose and schedule in circulation reflects self-directed gray-market practice rather than clinical guidance.
Subcutaneous injection is the route almost universally described for Melanotan II, because peptides of this class survive poorly in the digestive tract and absorb predictably through the fatty tissue just under the skin. Reports describe injection into the abdomen, thigh, or flank with a short-needle insulin syringe, with sites rotated to reduce local irritation. None of these routes has been validated in approved human use, and the descriptions reflect gray-market practice rather than clinical recommendation.
| Route | Absorption | What the literature reports |
|---|---|---|
| Subcutaneous | Predictable | Route almost universally described; injected into abdomen, thigh, or flank |
| Oral | Ineffective | Gastric acid and proteases degrade the peptide before it reaches circulation |
| Intranasal spray | Inconsistent | Marketed as needle-free, but mucosal uptake of a peptide this size is unpredictable and typically lower |
Subcutaneous injection is the only route users reliably describe for Melanotan II, since oral use is degraded by gastric acid and intranasal absorption of a peptide this size is inconsistent and typically lower than injection.
The two-phase pattern circulated in forums and vendor material splits use into a loading phase and a maintenance phase, though neither rests on clinical validation. Reported microgram amounts, loading lengths, and frequencies vary widely between sources, with no authoritative reference to reconcile them.
The dosing pattern most often circulated for Melanotan II is a self-directed loading phase of roughly 250 to 500 micrograms daily for one to two weeks, followed by maintenance dosing two or three times weekly, none of it clinically validated.
Reconstitution converts the sealed lyophilized powder into an injectable solution, and the concentration it produces determines every dose drawn afterward. Vendor inserts and forum protocols describe the same general method, but because there is no pharmacist oversight, arithmetic errors in the peptide-to-water ratio are a frequently cited source of accidental overdosing.
Published protocols describe reconstituting a 10-milligram vial with 2 milliliters of bacteriostatic water to reach 5 mg/mL, at which each unit on a U-100 insulin syringe delivers 50 micrograms, though miscalculation of this ratio is a frequently cited cause of accidental overdose.
No validated dosing standard exists because Melanotan II was never approved as a medicine in any jurisdiction. It originated in university research on melanocortin agonists but never completed the clinical development that defines a therapeutic window and produces approved labeling.
Melanotan II never completed clinical development or regulatory approval in any jurisdiction, so no therapeutic window or validated dose exists, and regulators in the US, UK, EU, and Australia actively warn against its use.
Peptide stability drives the storage practices users describe, though the shelf-life figures circulated are practical estimates rather than validated pharmaceutical data. Because no manufacturer stability testing stands behind an unregulated product, these handling cues function as informal safeguards, not guarantees of an accurate preserved dose.
Sealed lyophilized Melanotan II is reported stable when refrigerated or frozen and shielded from light, while a reconstituted solution is far more perishable, typically refrigerated and used within a few weeks, with cloudiness or particles treated as a reason to discard it.
Educational use only. This article describes what the published scientific and clinical literature reports about Melanotan II. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
